Results 91 to 100 of about 5,445 (182)
Renal Replacement Therapy, 2018 Background Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited disease among primary diseases in dialysis patients. Tolvaptan is known to improve increases in total kidney volume (TKV) in patients with ADPKD, thereby slowing
Shuma Hirashio +2 more
doaj +1 more source
Loop Diuretic Therapy in Severe Aortic Stenosis: Marker or Mediator of Adverse Outcomes?
Clinical Cardiology, Volume 49, Issue 1, January 2026.
Masaki Miyazawa, Teruhiko Imamura
wiley +1 more source
Cancer Medicine, 2017 Hyponatremia is a common electrolyte disorder in cancer patients and has been associated with poor prognosis. A frequent cause of cancer‐related hyponatremia is the syndrome of inappropriate antidiuretic hormone (SIADH).
Richard J. Gralla +6 more
doaj +1 more source
, 2020 Tolvaptan is a selective V 2 -receptor antagonist primarily metabolized by CYP 3A. The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for drug ...
Lu
core
Duloxetine-Induced Antidiuresis in Rats with Lithium-Induced Nephrogenic Diabetes Insipidus
LifeAntidepressants, including duloxetine, are a significant cause of drug-induced hyponatremia, which can disrupt the continuation of medication. Tolvaptan is beneficial for correcting hyponatremia caused by the syndrome of inappropriate antidiuresis, but ...
Sua Kim, Chor Ho Jo, Gheun-Ho Kim
doaj +1 more source
Tolvaptan slows disease progression in late-stage ADPKD
, 2018 New data from the REPRISE trial confirms that tolvaptan slows the progression of autosomal dominant polycystic disease (ADPKD). Although not yet approved by the United States Food and Drug administration, tolvaptan is now likely to become standard care ...
Ong, A.C.M.
core +1 more source
Frontiers in PharmacologyBackground: Tolvaptan, a selective vasopressin V2-receptor antagonist, can elicit a diuretic effect without significant electrolyte loss. The aims were to evaluate multiple-dose pharmacokinetics, pharmacodynamics and safety of daily administration of 15 ...
Hongzhong Liu +10 more
doaj +1 more source
Kidney International ReportsIntroduction: Tolvaptan has been shown to reduce renal volume and delay disease progression in autosomal-dominant polycystic kidney disease (ADPKD). However, no biomarkers are currently available to guide dose adjustment.
F.J. Roca Oporto +4 more
doaj +1 more source
The impact of tolvaptan on autosomal dominant polycystic kidney disease – literature review
Studia MedyczneThis article presents current data from international literature on the impact of tolvaptan on autosomal dominant polycystic kidney disease (ADPKD). The authors have reviewed the latest clinical research literature.
Anna Gruszczyńska +4 more
doaj +1 more source